Vaxart Appoints Biotech Veteran Dr. James Breitmeyer to Board of Directors
VXRT has more than doubled off its 52-week low of $0.261.
Summary
Vaxart appointed Dr. James Breitmeyer, a highly experienced biopharmaceutical executive, to its Board of Directors, bolstering its clinical development and regulatory expertise.
Key Events · Executive and Board Changes · VXRT
-
New Board Member Appointed
Dr. James B. Breitmeyer, M.D., Ph.D., was appointed to the Board of Directors, effective April 23, 2026.
-
Extensive Industry Experience
Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including CEO roles at Altay Therapeutics and Oncternal Therapeutics, and senior positions at Bavarian Nordic, Eli Lilly, and Cadence Pharmaceuticals, with a track record of eight FDA product approvals.
-
Strengthens Clinical and Regulatory Expertise
His appointment is expected to enhance the Board's capabilities in clinical development and regulatory strategy, crucial for Vaxart's oral vaccine platform, especially given the company's recent financial and strategic challenges.
Analysis · VXRT · Life Sciences
The appointment of Dr. James Breitmeyer, a seasoned biopharmaceutical executive with over 35 years of experience in clinical development and regulatory approvals, strengthens Vaxart's Board of Directors. His expertise is particularly valuable for a clinical-stage company like Vaxart, especially as it navigates recent financial challenges and strategic adjustments, including a going concern warning and recent capital raises. This move enhances the company's leadership and strategic capabilities.
At the time of this filing, VXRT was trading at $0.74 on OTC in the Life Sciences sector, with a market capitalization of approximately $178.6M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.